Hi-Tech Pharmacal Co. has been cleared to market bromfenac ophthalmic solution 0.09% (once a day) by the Food and Drug Administration.


Hi-Tech Pharmacal, bromfenac ophthalmic solution, Bromday ophthalmic solution, generic version, Ista Pharmaceuticals, Akorn, acquisition














































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Hi-Tech ships Bromday ophthalmic solution generic

January 23rd, 2014

AMITYVILLE, N.Y. – Hi-Tech Pharmacal Co. has been cleared to market bromfenac ophthalmic solution 0.09% (once a day) by the Food and Drug Administration.

Hi-Tech said Thursday that its product, a generic version of Ista Pharmaceuticals' Bromday ophthalmic solution 0.09%, is set to be released immediately.

Bromfenac ophthalmic solution is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

In late August, Hi-Tech agreed to be acquired by Akorn Inc. in a $640 million deal. Hi-Tech said it expects the acquisition transaction to be completed during the first quarter of 2014, pending regulatory approval and other customary closing conditions.

Advertisement